PURPOSE: Parents' stress levels are high prior to their child's hematopoietic stem cell transplant (HSCT) and during transplant hospitalization, usually abating after discharge. Nevertheless, a subgroup of parents continues to experience frequent anxiety and mood disruption, the causes of which are not well understood. The purpose of this study was to assess whether clinical complications of HSCT could explain variation in parents' recovery of emotional functioning. METHODS: Pediatric HSCT recipients (n = 165) aged 5-18 and their parents were followed over the first year post-transplant. Health-related quality of life assessments and medical chart reviews were performed at each time period (baseline, 45 days, 3, 6, and 12 months). We tested the association between clinical complications [acute and chronic graft versus host disease (aGVHD and cGVHD), organ toxicity, and infection] and longitudinally measured parental emotional functioning, as assessed by the Child Health-Ratings Inventories. The models used maximum likelihood estimation with repeated measures. RESULTS: In adjusted analyses covering the early time period (45 days and 3 months), aGVHD grade ≥2, intermediate or poor organ toxicity, and systemic infection were associated with decreases in mean parental emotional functioning of 5.2 (p = 0.086), 5.8 (p = 0.052), and 5.1 (p = 0.023) points, respectively. In the later time period (6 and 12 months), systemic infection was associated with a decrease of 20 points (p < 0.0001). cGVHD was not significantly associated. CONCLUSIONS: When children experience clinical complications after HSCT, parental emotional functioning can be impacted. Intervening at critical junctures could mitigate potential negative consequences for parents and their children.
PURPOSE: Parents' stress levels are high prior to their child's hematopoietic stem cell transplant (HSCT) and during transplant hospitalization, usually abating after discharge. Nevertheless, a subgroup of parents continues to experience frequent anxiety and mood disruption, the causes of which are not well understood. The purpose of this study was to assess whether clinical complications of HSCT could explain variation in parents' recovery of emotional functioning. METHODS: Pediatric HSCT recipients (n = 165) aged 5-18 and their parents were followed over the first year post-transplant. Health-related quality of life assessments and medical chart reviews were performed at each time period (baseline, 45 days, 3, 6, and 12 months). We tested the association between clinical complications [acute and chronic graft versus host disease (aGVHD and cGVHD), organ toxicity, and infection] and longitudinally measured parental emotional functioning, as assessed by the Child Health-Ratings Inventories. The models used maximum likelihood estimation with repeated measures. RESULTS: In adjusted analyses covering the early time period (45 days and 3 months), aGVHD grade ≥2, intermediate or poor organ toxicity, and systemic infection were associated with decreases in mean parental emotional functioning of 5.2 (p = 0.086), 5.8 (p = 0.052), and 5.1 (p = 0.023) points, respectively. In the later time period (6 and 12 months), systemic infection was associated with a decrease of 20 points (p < 0.0001). cGVHD was not significantly associated. CONCLUSIONS: When children experience clinical complications after HSCT, parental emotional functioning can be impacted. Intervening at critical junctures could mitigate potential negative consequences for parents and their children.
Authors: H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas Journal: Transplantation Date: 1974-10 Impact factor: 4.939
Authors: S I Bearman; F R Appelbaum; C D Buckner; F B Petersen; L D Fisher; R A Clift; E D Thomas Journal: J Clin Oncol Date: 1988-10 Impact factor: 44.544
Authors: Sharon Manne; Katherine Duhamel; Jamie Ostroff; Susan Parsons; D Richard Martini; Sharon E Williams; Laura Mee; Sandra Sexson; Jane Austin; Gary Winkel; Farid Boulad; William H Redd Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-09 Impact factor: 8.829
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: Christina K Ullrich; Angie Mae Rodday; Kristin M Bingen; Mary Jo Kupst; Sunita K Patel; Karen L Syrjala; Lynnette L Harris; Christopher J Recklitis; Grace Chang; Eva C Guinan; Norma Terrin; Hocine Tighiouart; Sean Phipps; Susan K Parsons Journal: Cancer Date: 2017-04-07 Impact factor: 6.860
Authors: Brian W Pennarola; Angie Mae Rodday; Kristin Bingen; Lisa A Schwartz; Sunita K Patel; Karen L Syrjala; Deborah K Mayer; Sara J Ratichek; Eva C Guinan; Mary Jo Kupst; Judith H Hibbard; Susan K Parsons Journal: Support Care Cancer Date: 2014-12-18 Impact factor: 3.603
Authors: Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala Journal: Biol Blood Marrow Transplant Date: 2016-09-19 Impact factor: 5.742
Authors: Stephen A Sands; Laura Mee; Abraham Bartell; Sharon Manne; Katie A Devine; Mirko Savone; Deborah A Kashy Journal: J Pediatr Psychol Date: 2017-04-01
Authors: Christina K Ullrich; Angie Mae Rodday; Kristin Bingen; Mary Jo Kupst; Sunita K Patel; Karen L Syrjala; Lynnette L Harris; Christopher J Recklitis; Lisa Schwartz; Stella Davies; Eva C Guinan; Grace Chang; Joanne Wolfe; Susan K Parsons Journal: Biol Blood Marrow Transplant Date: 2015-09-05 Impact factor: 5.742
Authors: Katie A Devine; Sharon L Manne; Laura Mee; Abraham S Bartell; Stephen A Sands; Shannon Myers-Virtue; Pamela Ohman-Strickland Journal: Support Care Cancer Date: 2015-11-17 Impact factor: 3.359